CRD Summary: This review assessed the effectiveness of linezolid for the treatment of patients with infective endocarditis. The authors concluded that limited data suggest that linezolid should be considered in patients with infective endocarditis with limited treatment options but randomised controlled trials are required. These conclusions reflect the evidence presented, but their reliability is limited by methodological weaknesses of the review.

[Two thirds of patients received linezolid alone, while others received linezolid in combination with rifampicin, gentamicin, fusidic acid or amikacin.]

CRD Commentary: The review addressed a clear question and was supported by appropriate inclusion criteria. Only one electronic database was searched, along with reference lists, to identify relevant studies, so relevant studies may have been missed and publication bias may be present. Also, the authors did not state whether any language restrictions were applied, so there is the possibility of language bias. The authors did not report the methods used for study selection or data extraction, so the possibility of reviewer bias and error cannot be excluded. The validity of the included studies was not formally assessed. Study details were tabulated with adequate information on participant characteristics and treatment regimen. The details of study results were limited. In view of the nature of the included studies and differences between studies, a narrative synthesis was appropriate. The authors' cautious conclusions reflect the evidence presented. but owing to the lack of reporting of review methods and the potential for publication and language bias, these conclusions may not be reliable.